To hear about similar clinical trials, please enter your email below
Trial Title:
Differentiated Thyroid Cancer Patients Treated With Different Doses of Radioactive Iodine.
NCT ID:
NCT06134830
Condition:
Thyroid Cancer
Conditions: Official terms:
Thyroid Neoplasms
Thyroid Diseases
Study type:
Observational
Overall status:
Not yet recruiting
Study design:
Time perspective:
Retrospective
Intervention:
Intervention type:
Drug
Intervention name:
RAI
Description:
Radioactive iodine
Summary:
1. Determine the frequency of utilizing single and multiple doses of radioactive iodine
(RAI) in treatment of differentiated thyroid cancer.
2. Asses the impact of various doses of radioactive iodine on the management of
differentiated thyroid cancer.
3. Investigate the influence of thyroid cancer on the quality of life of affected
patients.
Detailed description:
Differentiated thyroid cancer represents more than 90% of cancer thyroid [1]. Total
thyroidectomy is considered the mainstay of curative therapy, with radioactive iodine
(RAI) in order to ablate or treat remnant thyroid tissue in the surgical bed and/or
elsewhere [2]. The two main objectives for treatment of differentiated cancer thyroid are
reducing the probability of cancer recurrence and facilitating serological surveillance
via thyroglobulin (TG). The 2015 American Thyroid Association (ATA) guidelines as well as
European Consensus Conference described three main risk stratification for thyroid cancer
including: low, intermediate and high risk [3] [4]. According to the 2015 ATA guidelines,
low- dose (1110 MBq) 131I ablation is recommended for low-to- intermediate-risk patients,
while high-dose (3700 MBq or more) 131I ablation may be required for high-risk patients
to remove microscopic residual disease(4). The optimal RAI activity needed to achieve the
best objective RAI response and to minimize RAI specific adverse effects is not known
since there are many factors that should be considered while determining the dose
including age of the patient and many pathological factors [5, 6]. Therefore, dose
adjustment might be needed for patients with same risk classification. Just following the
guidelines might not be optimal for treatment of individual differentiated thyroid cancer
[5]. Accordingly, in our centre the administrated activities are varied among our
clinicians. In this study, we aim to retrospective analyse patients with differentiated
thyroid cancer received variable (single and multiple) doses of RAI in each risk group
and to assess their clinical outcome. As thyroid cancer has a very good prognosis, there
a debate that quality of life may be affected in patients with high risk compared to low
and intermediate risks. Additionally, we intend to evaluate the impact of thyroid cancer
on quality of life by questionnaire filled by patients with different risk groups.
Criteria for eligibility:
Study pop:
Patients with differentiated cancer thyroid treated at Assiut University Hospitals.
Sampling method:
Probability Sample
Criteria:
Inclusion Criteria:
- • Patients with differentiated cancer thyroid either papillary or follicular
underwent total thyroidectomy with or without lymph node dissection.
- Available data of patients' records.
Exclusion Criteria:
- • Missed follow up data.
Gender:
All
Minimum age:
N/A
Maximum age:
N/A
Start date:
March 1, 2024
Completion date:
January 1, 2027
Lead sponsor:
Agency:
Assiut University
Agency class:
Other
Source:
Assiut University
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT06134830
